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Machado–Joseph disease [MJD, also spinocerebellar ataxia type 3
(SCA3)] and familial amyloid polyneuropathy type I (FAP-I or ATTR
V30M) are neurodegenerative disorders, inherited in an autosomal
dominant fashion, which have a high prevalence in Portugal, probably
due to a founder effect. MJD and FAP-I are late-onset diseases, with
symptoms emerging usually during adulthood. CGPP, which is the
national reference centre for these disorders, has a genetic lab that offers
diagnostic, pre-symptomatic and prenatal testing and an outpatient
clinic to counsel and follow relatives at risk for hereditary ataxias, FAP-
I and Huntington disease (HD). The present work is a review of our 10-
year experience with psychological counselling of individuals at risk for
MJD and FAP-I. Persons at risk for FAP-I may show a better response
to pre-symptomatic testing than those who are at risk for MJD and HD
because of the availability of liver transplantation, which may improve
their health and life expectancy. Psychological well-being and specific
distress of MJD and FAP-I test applicants, before undergoing genetic
testing (baseline level) and 3 to 6 months after disclosure of test results,
have shown a low level of change, both in identified carriers and non-
carriers. A major goal of psychological characterization of at-risk indi-
viduals for MJD and FAP-I is to determine the factors that influence
the uptake of genetic testing.
L Rolima, Aˆ Leitea, S Leˆdoa,
M Panequec, J Sequeirosa,b and
M Fleminga,b
aCentro de Gene´tica Preditiva e
Preventiva (CGPP), Institute for Molecular
and Cell Biology (IBMC), bICBAS,
University of Porto, Portugal, and
cDepartment of Predictive Genetics,
CIRAH, Holguı´n, Cuba
Key words: familial amyloidosis – genetic
counselling – genetic testing – hereditary
ataxias – psychosocial genetics
Corresponding author: L. Rolim, CGPP-
IBMC, University of Porto, Campo Alegre,
823, 4150-180 Porto, Portugal.
Tel.: þ351 22 607 49 94;
fax: þ351 22 600 29 23;
e-mail: lrolim@ufp.pt
Received 16 November 2005, revised and
accepted for publication 22 February 2006
The genetic revolution of the last decades pro-
vided new tools for medical practice, such as
DNA-predictive testing for a broad range of dis-
eases. Pre-symptomatic DNA testing is currently
available for many late-onset neurogenetic disor-
ders; Huntington disease (HD) was the first to
use this new paradigm and has served as a model
for other neurodegenerative disorders (1–3).
Machado–Joseph disease (MJD), also known
as spinocerebellar ataxia type 3 (SCA3), and
familial amyloid polyneuropathy type I (FAP-I
or ATTR V30M), a peripheral neuropathy, are
two neurological, dominant disorders with late
onset, which are more frequent in Portugal than
in most other countries (4–6). Both are suitable
for diagnostic, pre-symptomatic, prenatal testing
and pre-implantation genetic diagnosis (6–10).
Our research centre has accumulated experience
regardingMJD and FAP-I (6–9, 11–15). As inHD,
asymptomatic individuals at risk for both those
late-onset diseases now can learn, through genetic
testing, their future risk of developing the illness
present in their families. Informed people are free
to decide whether or not to take the test. This
decision generates emotional distress and involves
major personal issues (16–18), with the potential
for short- to long-term psychological consequences
for the individual and his/her family (19, 20).
Clinical features of MJD
MJD is a SCA, with an autosomal dominant
inheritance, which impairs postural balance and
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coordination of all body movements, including
gait, speech and fine movements of the hands
(21, 22). Symptoms start late, at an average age
of 40.2 years (43.7 years for women and 37.3
years for men). MJD also presents with ocular
anomalies (limitation of eye movements and
diplopia), dystonia, peripheral amyotrophies
and decrease in vibration sense. There is neither
mental deterioration nor loss of sphincter con-
trol. No treatment is currently available to pre-
vent or delay the appearance of the disease. MJD
was firstly described in the USA by Nakano and
colleagues (23), where it affected predominantly
people with ancestry from the Atlantic islands of
the Azores who are living mainly in Portugal,
USA, Canada and Brazil (22, 24, 25). MJD is
due to the expansion of a CAG repeat (as in
HD) within the coding region of MJD/ATXN3
gene on chromosome 14q32.1 (26, 27). It is the
most prevalent SCA worldwide (28). The highest
incidence (about 1 : 4000) is among Azoreans, in
Portugal, the USA, Canada and Brazil; in Flores
(a Portuguese island of the Azores), MJD reaches
the highest prevalence (1 : 140) reported world-
wide (22).
Clinical features of FAP-I
FAP-I (ATTR V30M) is also a severe autosomal
dominant disorder that was first described by the
Portuguese neurologist Corino Andrade (4, 29).
The original mutation may have occurred or been
introduced, many centuries ago, in an individual
from Po´voa, a fishermen settlement on the north-
ern coast of Portugal (30). FAP-I has propagated
along the Portuguese coast and throughout the
world, possibly during the pioneering sea travels
of Portuguese sailors in the XV and XVI centu-
ries (30). FAP is present also in a number of
other countries, such as Japan (the second largest
focus), Brazil, Sweden and some Mediterranean
countries (30, 31). The north of Portugal has a
high prevalence rate: in 1991, this was estimated
as 105 : 105 in Po´voa de Varzim and Vila do
Conde (32). In Portugal, over 1700 patients,
from 500 unrelated kindreds, have been regis-
tered at the Centro de Estudos de
Paramiloidose, representing the largest concen-
tration of FAP in the world (33).
FAP-I results from a single mutation in the
TTR gene, located on chromosome 18q11.2-
12.1, leading to a sensory motor neuropathy
with autonomic dysfunction. The mutation
leads to the production of an abnormal trans-
thyretin (TTR V30M), which is degraded,
bound and precipitated in tissues as amyloid
fibrils (34). The mutant TTR was then identified
(34), which allowed for the identification of FAP-
I patients all over the world (35). The mean age
of onset of FAP-I is 33.5 years, but it can start
between 17 and 78 years of age (8). FAP-I dura-
tion is, on average, 11 years. Liver transplanta-
tion is the only medical procedure that seems to
slow down the progress of symptoms of FAP-I
(36, 37).
DNA pre-symptomatic testing
The identification of the relevant genes for MJD
and FAP-I allowed the molecular diagnosis, as
well as pre-symptomatic testing of at-risk
persons.
It is pertinent to recall some early lessons
learned from HD pre-symptomatic testing. It is
clear that genetic testing should be offered as part
of a protocol by a multidisciplinary team, which
should include a clinical geneticist, a clinical psy-
chologist, a neurologist and a social worker. At
least two pre-test counselling sessions and several
follow-up sessions are offered to at-risk indivi-
duals to meet their information and emotional
needs (2, 38–40), which facilitate decision-making
and aim to anticipate and prevent adverse
responses to genetic testing (41). This approach
has been a widely accepted model for other late-
onset neurodegenerative diseases, such as MJD
and FAP-I (7, 8, 17–19, 42–44).
In Portugal, genetic counselling and pre-symp-
tomatic testing is being offered, at our center, to
all adults at risk for MJD since 1995 (7, 45). A
major aim of this program is to help those who
come to us to be informed about their genotype:
we provide them medical, psychological and
social support, to facilitate informed decisions
and coping in a healthy manner with the results
disclosed after pre-symptomatic testing.
In FAP-I, detection of the abnormal TTR has
been made, since 1984, in individuals at risk for
this disease (34). Since 1999, genetic counselling
and psychosocial support have been provided
also at our centre for all individuals who search
pre-symptomatic testing, taking advantage of the
same protocol as for HD and MJD.
Genetic risk
The threat posed by a hereditary disease causes
significant emotional burden on individuals at
risk, as well as on their families (46). Although
research in this area is still scarce, several authors
have studied the psychological dynamics and
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life-long endeavour of living with the risk for a
serious genetic disease. The risk status, in parti-
cular for late-onset diseases such as HD, MJD
and FAP-I, represents a chronic stress because of
the feeling of uncertainty and the anxiety experi-
enced (47).
Wexler (48) illuminated the psychological con-
tour of this peculiar state with the metaphor of
the ticking bomb, to illustrate the expectant anxi-
ety with which at-risk individuals keep awaiting
the first symptoms of the disease. Boutte´ (49)
stated that the experience of being at risk for
MJD and the state of living constantly in that
tenuous limbo between being or not being a car-
rier may be experienced as a second family
disease.
The hereditary character of MJD and FAP-I,
and the inherent risk of transmission to offspring,
influences the organization of the family, its
beliefs and its identity. Family experiences of
genetic risk, and the particular life events that
are related to the disease, may develop into dis-
tinctive life expectations in each of its members,
as well as in the family as a system: family mem-
bers’ timetables become shaped by the timetable
of the illness (50).
Genetic counselling
In pre-symptomatic genetic testing programs,
genetic counselling starts from the moment
when individuals are informed about their state
of risk and the availability of genetic testing, for
early definition of their carrier or non-carrier
status, and offer of prenatal diagnosis (51).
The potential advantages for individuals at risk
who submit themselves to genetic counselling and
testing programs are emotional relief, ameliora-
tion of anxiety and guilt feelings, discussion and
analysis of the most favourable behaviours,
reproductive choices and coping styles. In the
specific case of pre-symptomatic testing, genetic
counselling is related to decision-making pro-
cesses on whether to determine or not the risk
of later suffering from the disease and the risk of
transmitting it to their offspring. One of the
advantages of knowing their carrier status is the
chance to better plan the future so that the most
appropriate life conditions may be planned, both
for the individuals and their offspring (52).
The potential effects of genetic counselling on
the decision to be tested or not, and on under-
standing information about costs and benefits of
doing so, have been explored by several studies,
which we describe below.
Relevance of genetic counselling protocols
Although this overview is devoted to MJD and
FAP-I, it is pertinent to recall briefly some
relevant information obtained from individuals
at risk for HD, which has been serving as a
frame of reference for other late-onset genetic
conditions. For instance, in a survey carried out
among six-hundred families, when HD pre-
symptomatic testing was still performed by
linkage analysis and beginning to be offered,
the authors (53) concluded that at-risk individ-
uals were aware of the advantages of genetic
counselling to facilitate the acquisition and com-
prehension of the predictive testing results; and,
unexpectedly, this sort of information has not
led to significant clinical anxiety levels. Studies
of the attitudes of 69 individuals at risk for HD
estimated that at least 2–6% may have severe
psychiatric or suicidal responses to a carrier
result (54). A study of the predictive testing
program in Canada revealed that 96% of the
participants expressed satisfaction with it (55).
The fact that individuals and their families
had suitable counselling and were given the
opportunity to discuss and consider future
implications of the test results was considered
of key importance (55).
In general, there are infrequent adverse
outcomes in HD pre-symptomatic testing when
careful counselling protocols were followed (56).
However, the impact of being diagnosed as a
carrier of the HD mutation is significant (40,
57), but this distress associated with testing
might be reduced by careful counselling and
support before and after testing (58).
All prior data underscore the need for careful pre-
and post-test counselling and for the professional
and community resources required to deal with the
psychological burden of pre-symptomatic testing on
both testees and their relatives.
Regarding FAP-I, Zagalo-Cardoso (59) studied
the attitudes of at-risk individuals facing predic-
tive testing and concluded that the best predictors
for a good outcome were (i) having previous
knowledge about the disease and the testing
process, (ii) an accurate perception of the disease
burden, (iii) the genetic results received from the
testing and (iv) the educational level of the
individual having the lowest predictive value.
Individuals informed that they were carriers
(n ¼ 47) had less-favourable outcomes than
non-carriers (n ¼ 29). But, this was at a time
when proper genetic counselling protocols, with
multiple sessions and psychosocial evaluation
and follow-up, were not yet available for these
patients.
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Our experience with MJD and FAP-I suggests
that it is useful to distinguish three occasions for
genetic counselling: (i) before testing is per-
formed, when counselling is useful to help the
decision-making process, (ii) while testees are
awaiting for test results, when counselling helps
dealing with stress and anxiety of the anticipated
news and (iii) after disclosure of their true genetic
status, when counselling is of particular impor-
tance to help people deal with the impact of the
results. Post-test sessions should also be offered
to non-carriers, because these individuals also
suffer psychological distress, namely feelings of
guilt or shame in relation to close relatives that
are carriers or already affected (17, 18, 60, 61).
Influence of genetic counselling on marriage and
pregnancy decision-making
A total of 61% of individuals at risk for MJD,
living in the Azores Islands, Portugal, reported
that carrying the mutation would lead them to
the decision to not have children (62). The influ-
ence of the risk status was also reflected in these
different attitudes of at-risk individuals and by the
group of affected people, who needed to consider
(i) whether to undertake prenatal diagnosis and (ii)
in case the MJD mutation was detected, to decide
whether to interrupt the pregnancy. Acceptance of
prenatal diagnosis and termination of pregnancy in
the presence of the mutation in the foetus was low.
In HD, among 390 candidates in pre-sympto-
matic testing, only 43% stated that they would
make use of prenatal diagnosis, and only 17%
would interrupt pregnancy in the case of a carrier
test result (63).
With regard to FAP-I, attitudes towards pro-
creation, among 70 individuals at risk, depended
mostly on educational level and their knowledge
about the disease and pre-symptomatic diagnosis:
a higher degree on any of these was associated with
a worse attitude towards procreation (59). In fact,
a stepwise multiple regression analysis showed that
these variables accounted for 23% of the total
variation in attitudes towards procreation. This
study also indicated that there were no differences
between FAP-I carriers and non-carriers, in regard
to attitudes towards marriage and procreation.
Summary of genetic counselling studies
Appropriate implementation of pre-symptomatic
and prenatal testing calls for genetic counselling
protocols: (i) to guide the decision-making pro-
cess before testing; (ii) while subjects are awaiting
the result and (iii) after results are disclosed.
Post-test sessions should be offered also to
those who receive favourable results, as these
people may also suffer psychological distress.
The importance of genetic counselling and regu-
lar psychological support is well known in dimin-
ishing the emotional impact of the test results (56),
although research to date has been scarce in long-
itudinal approaches, which might identify factors
that influence adaptation to the test results. In a
prospective study of 135 participants in the
Canadian program for HD testing, there was a
psychological evaluation of the counselees, at inter-
vals of 7–10 days, 6 months and 12 months after
receiving their test results (64). Receiving the results
of pre-symptomatic testing, even if it indicated an
increased risk, could reduce uncertainty and pro-
vide an opportunity for appropriate life planning.
Therefore, individuals who undergo genetic testing
may derive psychological benefits from it.
Huggins and colleagues (65) studied individuals
who had received, 2 years before, the result of a
low risk for HD. The authors found that 10% had
difficulties in coping with their status. These were
the persons who had already made irreversible life
decisions, based on the belief that they would
develop HD, or those who had unrealistic expec-
tations of the positive effects that would come
from a diagnosis of low risk for this disease.
According to a worldwide survey on cata-
strophic events, organized by the Vancouver
group, involving 4527 test participants (66), sui-
cide attempts after HD pre-symptomatic testing
were very rare. Another study by Almqvist and
colleagues (67) assessed prospectively (over
5 years) the psychological consequences of pre-
dictive testing in individuals at risk for HD. A
significant reduction in psychological distress was
observed throughout 2 years and at 5 years; how-
ever, 6.9% (14 of 202) of the participants experi-
enced a clinically significant adverse event during
the first 2 years after undergoing predictive test-
ing. These occurred more frequently in the group
with increased risk for HD and mostly within 12
months after receiving the genetic results.
A healthy adaptation to genetic diagnosis has
been attributed mainly to appropriate genetic
counselling and psychological support within pre-
symptomatic testing programs (61).
Pre-symptomatic testing
Decision-making
A number of authors (68–72) have studied adher-
ence to pre-symptomatic testing in MJD and
explored predictors of genetic testing uptake.
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From the counselees’ point of view, benefits of
having pre-symptomatic testing for MJD
included a reduction in the level of uncertainty
and the chance to plan their future, with regard
to procreation and to the disease itself (69). Other
benefits referred were the possibility of informing
the offspring about the risk of developing the
disease or even the chance of beginning a medical
treatment (not yet available), to prevent its devel-
opment and/or delay its course (68, 70, 73). The
arguments mentioned by at-risk individuals
against taking predictive testing for MJD were
the anticipation of negative consequences from a
carrier result, namely the emotional conse-
quences on the family and peer groups, as well
as difficulties in coping with the potentially tragic
future of this debilitating disease.
Regarding predictive testing for FAP-I, several
problems were raised by at-risk individuals (8).
One of these was the perceived disadvantage of
exchanging a 50% chance of being a carrier for
the known certainty offered by the test, if the
results were unfavourable. Some felt that this
might be intolerable for them and would prefer
not to bear any children than to live long years
with the prospect that they will certainly suffer
from FAP-I in the future. What may be consid-
ered as advantageous and justifiable reasons
from the medical and public view point (e.g.
planning for the future, helping in the choice of
a profession, family planning, improving quality
of life and contributing to health) may not be
recognized as such by the individual (18).
Hence, rejection of predictive testing may reflect
the perception that genetic knowledge will inevi-
tably have damaging consequences. Of a group
of 126 at-risk individuals that were tested for
FAP-I in the early years (8) – when no proper
pre- and post-test counselling was provided, 58%
stated they took the test because of medical
advice, rather than this being a free decision;
and, among these, 19% never came back to ask
for the result.
In FAP-I, in contrast with MJD, there is nowa-
days one feature that significantly alters the psy-
chological burden imposed by the disease, and
that may increase uptake of at-risk individuals
to pre-symptomatic testing: FAP-I patients are
now offered liver transplantation, which may
delay the progression of the disease (37).
Patients and their families now see FAP-I as
being less threatening than other neurodegnera-
tive diseases, such as MJD and HD (36). This is
not surprising if one considers that research in
other areas has shown that the availability of
therapy or preventive measures for a serious
disease may increase acceptance of genetic testing
(74). For example, in inherited breast cancer,
adherence to testing can reach 89% (75); on the
contrary, whenever these measures are rare or
inexistent, the uptake rate is greatly reduced (58).
Preparing in advance for liver transplantation
is often cited by the individual at risk for FAP-I
as one of the main reasons for taking the pre-
symptomatic test. In fact, the informed at-risk
individuals know that, if they are V30M muta-
tion carriers, they will have the chance to register
in a waiting list for a liver transplantation once
the onset of FAP-I is diagnosed. Because of the
availability of this therapy, predictive testing for
FAP-I might be perceived as very positive for the
tested individual (36). This does not mean, how-
ever, that psychological support to FAP-I at-risk
individuals, who ask to take the test, should be
neglected. Liver transplant is not a trivial proce-
dure and is certainly not the ‘cure’ for this dis-
ease. Thus, support should be pursued, whether
or not transplantation takes place, and should
continue before and after surgery.
Psychological effects
Research on the psychological effects of pre-
symptomatic testing is very important, as access
to test by at-risk individuals is becoming a reality
for many diseases.
The diagnosis of a serious disease such as FAP-
I is experienced, by gene carriers and patients, as
a significant loss. Interestingly, we have found
the following psychological characteristics in
these patients: (i) their most-frequent complaints
are anxiety and/or sadness and discouragement;
(ii) they present with high levels of difficulty in
communicating their emotions; (iii) they use
denial as their main defence mechanism to deal
with the pain associated with the knowledge of
having the disease and as a consequence (iv) most
of them fail to ask for psychological help. FAP-I
patients also have an internal experience of the
disease that is built on their knowledge from
previous generations, i.e. they often see them-
selves as a mirror of their affected parent (76).
Psychological well-being in persons at risk for
HD,MJD and FAP-I coming for pre-symptomatic
testing, evaluated by the Psychological General
Well Being (PGWB) Schedule, was compared
with that in the general population (71).
Surprisingly, the individuals at risk presented
with less anxiety and higher well-being indi-
cators than the control group. The authors
suggested that this could be explained by the
fact that at-risk individuals that came to the
first session of the protocol were psychologically
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more motivated and resilient, which might be due
to their own self-selected (persons less motivated
and prepared would exclude themselves from
taking the test).
At our research centre, a recent study on pre-
symptomatic testing for FAP-I (73) investigated
the psychological effects of receiving a carrier
result in 70 at-risk individuals (44 females and
26 males; mean age 24.3 years). Depression, mea-
sured by the Beck Depression Inventory (77), and
hopelessness, evaluated by the Beck Hopelessness
Scale (78), were used as indicators of their psy-
chological mood on three occasions: (i) before
testing, (ii) 3 weeks and (iii) 6 months after test-
ing. The scores for depression and hopelessness
did not reach pathological levels, at any moment,
for the vast majority of subjects. Nevertheless,
mean depression scores were higher before test-
ing and lowered three weeks after the carrier
result was disclosed; only 12 individuals (17%)
presented scores 9, indicating moderate depres-
sion. A t-test showed, however, that the differ-
ences between those two timings were not
statistically significant (p ¼ 0.293). Six months
after receiving the results, the majority (n ¼ 32,
86.5%) of the subjects that were informed that
they were carriers of the mutation were optimistic
about their future. These results suggested that,
on average, receiving a carrier result for FAP-I
seemed not to have a negative psychological
impact or to change the individuals hope for
their future.
In Japan, the psychological consequences of
genetic testing have been studied in two SCAs
(79): SCA1 and MJD (SCA3). Anxiety and social
desirability were assessed and analysed both in
patients (n ¼ 37) and in at-risk family members
(n ¼ 25). The SCA patients were found to have
higher baseline scores for anxiety than their
asymptomatic family members. Genetic testing
did not significantly increase the scores for all
patients or their asymptomatic family members,
who were tested, whereas anxiety was greatly
reduced in those who had received non-carrier
results.
The impact of pre-symptomatic testing for
MJD in 19 individuals at risk, in the Azores,
has also been studied (72). Depression and anxi-
ety were evaluated before testing, 3 weeks and 9
months after disclosure of the test result. The
majority of subjects did not reach pathological
levels of depression (92.3%; 12 of 13) and anxiety
(85.7%; 12 of 14), and knowledge of the results
proved not to have a negative long-term psycho-
logical impact, highlighting their capacity for
adaptation to a new and definitive genetic status.
At our research centre, only a small number of
couples (83, so far, including the first two cases of
prenatal testing for MJD) (11, 80) have come for
prenatal diagnosis of HD, MJD or FAP-I. A few
others have undergone or are currently under-
going pre-implantation genetic diagnosis for any
of these diseases.
Conclusions
Clearly, our national program for pre-
symptomatic testing and genetic counselling
of late-onset neurological disorders, which has
now been running for one decade (10 years for
MJD, and 7 and 6 years for HD and FAP-I,
respectively), will require re-evaluation and con-
tinuous improvement in its psychosocial assess-
ment and intervention protocols. This is
particularly important in Portugal because of a
regional high prevalence for FAP-I and for MJD,
which represent serious public health problems in
some areas of the mainland and the Azores. Our
experience shows that genetic testing for late-onset
neurological diseases calls for special attention
from psychologists and other health profes-
sionals in the application of genetic counselling
and psychosocial support protocols.
We believe that psychological intervention in
genetic testing programs for MJD and FAP-I
must include, in the future, the following goals:
(i) understanding the reasons why at-risk
individuals may decide to have (or not to have)
the test, (ii) determining their expectations
towards pre-symptomatic testing and its results,
(iii) to help individuals anticipating and consid-
ering personal advantages and disadvantages of
having the test and (iv) to help them integrating,
both cognitively and emotionally, the results of
the test.
We are further developing a number of research
areas (i) to identify the possible psychosocial pre-
dictors of uptake of testing, (ii) to predict the risk
of psychological disturbances and the social
impact after changing genetic status, (iii) to
improve psychological evaluation protocols and
tools in the pretest phase, to increase their sensi-
tivity in identifying the subjects psychologically
more vulnerable to adverse reactions and (iv) to
develop efficient psychological intervention stra-
tegies, aimed at preventing emotional risk and
helping subjects to deal with the burden caused
both by the decision-making process and the
genetic result itself.
Till now, investigations have been limited to
individuals who participate in genetic counselling
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programs. In particular, those who do not parti-
cipate should also be a subject of research. Also,
longer term follow-up of individuals who under-
went genetic testing forMJD and FAP-I is needed
to assess the later impact of testing and also to
determine the best predictors of psychological
response to genetic results.
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